Evaluating the Clinical Efficacy of Thulio vs. Holmium Laser Enucleation of the Prostate
NCT: NCT07187180 · RECRUITING
Brief Summary
Many consider laser enucleation of the prostate the new 'gold standard' for the surgical treatment of benign prostatic hyperplasia (BPH) due to its excellent outcomes, high success rates, and long-term efficacy. Holmium laser enucleation of the prostate (HoLEP) was the earliest form of prostate enucleation and is recommended by the American Urological Association (AUA), along with thulium laser enucleation of the prostate (ThuLEP), as size-independent techniques for the management of BPH with fewer complications than transurethral resection of the prostate (TURP). Further development of laser technology has additionally led to enucleation using pulsed-modulated (e.g. "Virtual Basket™" mode or MOSES™ mode) holmium lasers as well as the thulium fiber laser.
Frequently Asked Questions
What is Evaluating the Clinical Efficacy of Thulio vs. Holmium Laser Enucleation of the Prostate?
Evaluating the Clinical Efficacy of Thulio vs. Holmium Laser Enucleation of the Prostate is a clinical trial registered under NCT07187180. Current status: RECRUITING.
What is the status of NCT07187180?
The current status of NCT07187180 (Evaluating the Clinical Efficacy of Thulio vs. Holmium Laser Enucleation of the Prostate) is: RECRUITING.
When did Evaluating the Clinical Efficacy of Thulio vs. Holmium Laser Enucleation of the Prostate start?
Evaluating the Clinical Efficacy of Thulio vs. Holmium Laser Enucleation of the Prostate started on 2025-06-02.
Related Devices
Official Source
View on ClinicalTrials.gov →Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.